Bladder cancer presents a clinical paradox where men suffer higher incidence but women face worse outcomes. However, recent advances in bladder cancer gene expression research now provide clarity on these differences. A study of 51 patients used transcriptome sequencing to compare tumor tissues with healthy mucosa. The results highlight a major divergence in how the disease manifests at a molecular level between sexes.

How Bladder Cancer Gene Expression Varies

The research revealed that males have far more upregulated genes in tumor tissues compared to females. Specifically, the study identified 3,989 genes unique to male patients, while only 753 were unique to females. Male-specific expression patterns linked predominantly to cell cycle regulation and androgen receptor signaling. In contrast, female-specific patterns showed significant enrichment in immune-related pathways. These pathways include lymphocyte differentiation and leukocyte activation, which may influence how women respond to immunotherapy. Notably, overwhelmingly more upregulated genes appeared in male tissues than in female tissues during the comparison.

The Significance of S100A14

Notably, a two-factor interaction model pinpointed S100A14 as a critical sex-dependent gene. This protein-coding gene showed a significant interaction effect, suggesting it functions differently in male and female bladders. Furthermore, genes like GJB2 and DSC2 also showed probable sex-dependent interactions. These findings are essential because they provide a foundation for precision medicine. Therefore, doctors can potentially use these biomarkers to tailor surveillance and treatment plans more effectively. Indeed, the identification of these unique markers could pave the way for gender-specific therapeutic approaches.

Ultimately, this research underscores the necessity of considering biological sex in urological oncology. While clinicians currently use similar protocols for both genders, the molecular evidence suggests a need for sex-specific management. Future studies must validate these findings to improve survival rates and reduce recurrence for all bladder cancer patients.

Frequently Asked Questions

Why is bladder cancer gene expression different in men and women?

Differences arise due to sex chromosomes, hormonal signaling, and distinct immune responses. These biological factors drive unique molecular pathways in tumor development, leading to different clinical presentations.

What is the role of S100A14 in bladder cancer?

S100A14 is a protein-coding gene that exhibits a unique sex-dependent expression pattern. Researchers consider it a potential biomarker that could guide personalized treatment strategies in the future.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice and should not be used for diagnosis or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Zeber-Lubecka N et al. Sex-related differences in gene expression in early-stage bladder cancer revealed by whole-transcriptome sequencing. BMC Cancer. 2026 Feb 09. doi: 10.1186/s12885-026-15666-3. PMID: 41663990.

Mun DH, Kimura S, Shariat SF, Abufaraj M. The impact of gender on oncologic outcomes of bladder cancer. Curr Opin Urol. 2019 Mar;29(2):279-285. doi: 10.1097/MOU.0000000000000606.

Yao R et al. Expression profile and functional role of S100A14 in human cancer. PeerJ. 2019 Apr 26;7:e6812. doi: 10.7717/peerj.6812.